Core Insights - Defence Therapeutics Inc. is participating in CPHI Worldwide 2025, a major global pharmaceutical trade fair in Frankfurt, Germany from October 28-30, 2025 [1][2] Company Overview - Defence Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) using its proprietary ACCUM® technology, which enhances the precision delivery of ADCs to target cells, thereby increasing efficacy against cancer [6] Event Participation - The company aims to engage with potential partners across the biopharma value chain and connect with the global pharmaceutical community to learn about the latest trends in pharmaceutical manufacturing [2] - Defence Therapeutics is hosting a Meet & Greet event on October 29, 2025, from 4:30-6:30 PM at the Kimpton Hotel in Frankfurt, providing an informal setting for networking and exploring partnership opportunities [3][4] CPHI Overview - CPHI is a leading global pharmaceutical trade show expected to attract over 62,000 visitors and around 2,400 exhibiting companies in 2025, featuring more than 180 international speakers [5]

Core Insights - Defence Therapeutics Inc. has appointed Dr. Mark Lambermon as Head of Quality and Operations, bringing over 20 years of experience in pharmaceutical R&D and biotech innovation [1][2] - Dr. Lambermon's expertise will be crucial for the company's regulatory readiness and operational excellence as it advances its drug delivery technologies [3] - The company has granted Dr. Lambermon 100,000 incentive stock options, exercisable at $0.80 per share for three years [4] Company Overview - Defence Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) using its proprietary ACCUM® technology, which enhances the precision delivery of ADCs to target cells [5]

Group 1 - Defence Therapeutics Inc. has successfully closed a non-brokered private placement of debenture units, raising a total of $2,000,000 [1][5] - Each debenture unit consists of one $1,000 principal amount 8.0% convertible debenture and 1,666 common share purchase warrants [1][2] - The debentures have a maturity date of September 15, 2027, and are convertible into common shares at a price of $0.60 per share [2][3] Group 2 - The company paid a total of $160,000 in cash finder's fees and issued 266,667 finder's warrants, which are also exercisable at $0.75 per share [4] - The net proceeds from the offering will be used to advance the company's science programs and for general working capital [5] - All securities issued are subject to a statutory hold period of four months plus a day from their date of issue [5] Group 3 - Defence Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) using its proprietary ACCUM® technology [7]

Core Viewpoint - Defence Therapeutics Inc. is conducting a non-brokered private placement of debenture units to raise up to $1,200,000, aimed at enhancing its drug delivery technologies [1][2]. Financing Details - The offering consists of debenture units priced at $1,000 each, with a total gross proceeds target of $1,200,000 [1]. - Each unit includes one $1,000 principal amount of an 8.0% convertible debenture and 1,666 common share purchase warrants [1][2]. - The debentures will bear an interest rate of 8.0% per annum and will mature two years from the issue date [2]. - The principal amount of each debenture is convertible into common shares at a conversion price of $0.60 per share [2]. - Accrued interest can be paid annually in shares at the conversion price or in cash at the company's discretion [2]. Warrant Details - Each warrant allows the holder to acquire one common share at an exercise price of $0.75 for a period of two years from the issue date [3]. Regulatory and Compliance Information - All securities issued will be subject to a statutory hold period of four months and one day following the closing date [4]. - The completion of the offering is contingent upon receiving all necessary regulatory approvals [4]. - The company may pay a finder's fee to eligible arm's length finders in accordance with Canadian Securities Exchange policies [4]. Company Overview - Defence Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) using its proprietary ACCUM® technology, which enhances the precision delivery of ADCs to target cells, thereby increasing efficacy against cancer [6].

Core Insights - Defence Therapeutics Inc. is advancing its ADC and Radiopharma programs, focusing on collaborations and preclinical studies for cancer therapies using its Accum® technology [1][2][3] ADC Program - Defence's Accum®-based ADCs show improved intracellular delivery and cytotoxic activity in various preclinical cancer models compared to traditional ADCs [2] - The company is optimizing additional Accum®-based ADCs to enhance their value and attract potential licensing and co-development opportunities with Pharmaceuticals and Biotech companies [2] Radiopharmaceutical Program - The Radiopharma program is enhancing Accum® radiolabelling through studies conducted by Canadian Nuclear Laboratories, focusing on biodistribution, pharmacokinetics, and therapeutic potency [3] - The application of Accum® technology in the radiopharmaceuticals sector is expected to be transformative [3] Market Outlook - The global ADC market is projected to grow from USD 13.51 billion in 2025 to USD 29.9 billion by 2034, with a CAGR of 9.23% from 2024 to 2034 [4] - The global radiopharmaceutical market is expected to reach USD 16.87 billion by 2033, growing at a CAGR of 9.9% during 2025-2033 [4] Future Developments - The company plans to announce key results and partnership details as they become available, while continuing its studies in Canada and expanding its presence to the US [5] - Defence Therapeutics is a clinical-stage biotechnology company focused on developing next-generation ADC products using its proprietary Accum® technology [6]

Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON AUGUST 12, 2024 THE SECURITIES ACT OF 1933 Biodexa Pharmaceuticals PLC (Exact name of registrant as specified in its charter) (State or Other Jurisdiction of Incorporation or Organization) England and Wales 2834 Not Applicable (Primary Standard Industrial Classification Code Number) (IRS Employer Identification No.) Caspia ...